Dr. Reddy's Laboratories Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed a Pre-License Inspection (PLI) at the company's biologics manufacturing facility located in Bachupally, Hyderabad.

According to the company's regulatory filing, the inspection was conducted from June 16 to June 25, 2026. At the conclusion of the inspection, the USFDA issued a Form 483 containing seven observations.

India's manufacturing footprint is expanding, biosimilars are gaining momentum, and FDA inspections are evolving. The latest U.S. pharmaceutical quality report offers important insights for Indian manufacturers, exporters, regulators, and pharmacy professionals.

Researchers from the University Hospital Bonn (UKB) and the University of Bonn have developed a new laboratory model that enables scientists to generate and study follicular regulatory T (Tfr) cells, a specialized group of immune cells responsible for controlling antibody responses. The breakthrough is expected to accelerate research into autoimmune diseases, vaccine responses, and immune regulation. The findings have been published in the journal Cellular & Molecular Immunology.